Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 9/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282399 | 0.92 | NPBWR1 (0.54) | NPBWR1MCHR1NPSR1MAPTTP53 | |
| SCHEMBL4930954 | 0.92 | NPBWR1 (0.55) | NPBWR1MCHR1NPSR1MAPTGPR119 | |
| SCHEMBL14282396 | 0.91 | NPBWR1 (0.54) | NPBWR1MCHR1NPSR1MAPTTP53 | |
| SCHEMBL14220819 | 0.90 | NPBWR1 (0.52) | NPBWR1MCHR1NPSR1MAPTGPR119 | |
| SCHEMBL14282240 | 0.84 | NPBWR1 (0.53) | NPBWR1MCHR1NPSR1MAPTTP53 | |
| SCHEMBL14282285 | 0.84 | NPBWR1 (0.49) | NPBWR1MCHR1NPSR1MAPTTP53 | |
| SCHEMBL14282347 | 0.81 | MCHR1 (0.56) | NPBWR1MCHR1NPSR1 | |
| SCHEMBL4670543 | 0.81 | NPBWR1 (0.59) | NPBWR1MCHR1NPSR1 | |
| SCHEMBL4672514 | 0.81 | NPBWR1 (0.47) | NPBWR1MCHR1NPSR1 | |
| SCHEMBL14282221 | 0.80 | NPBWR1 (0.52) | NPBWR1MCHR1NPSR1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | LOXL1, LOXL2, LOXL3 | NPBWR1 733/4885MCHR1 1304/4885NPSR1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.